^
Association details:
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
Excerpt:
CLL/SLL with del(17p)/TP53 mutation: Relapsed/refractory therapy...Preferred regimens…Venetoclax + rituximab (category 1)